Abstract

Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

This disclosure relates to aminopyridine compounds of Formula (I) and (I') as positron emission tomography tracers for detecting demyelination in a subject suspected of having a neurological disorder and methods of manufacture and of uses thereof.

IPC Classes  ?

• C07D 213/61 - Halogen atoms or nitro radicals
• C07D 213/73 - Unsubstituted amino or imino radicals
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention relates to a method of diagnosing a subject with prostate cancer, the method comprising identifying hippurate, hippuric acid, or both in a urine sample from the subject, wherein the quantity of hippurate, hippuric acid, or both is utilized in providing patients with a diagnosis and prognosis for prostate cancer.

IPC Classes  ?

• G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance

Abstract

e.g.e.g., a fluorescent signal). In some aspects, such methods are useful for diagnosing and treating a subject such as a subject having a cancer.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

The present disclosure relates to compositions having a lipid-like compound of Gm-Cn, as well as methods of making and using such compositions. Also described herein are methods of treating cancer using such compounds with a combination therapy.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

Disclosed herein are compositions and methods for attenuating detoxification response and related symptoms thereof induced by translation defect. The compositions and methods herein are useful for attenuating detoxification response and/or treat related symptoms thereof in subjects comprising translation defect. The composition and methods herein are also useful for improving pharmacokinetics of a pharmaceutical compound.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 35/74 - Bacteria
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 39/00 - General protective or antinoxious agents
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Disclosed herein are methods and compositions useful for the treatment of subjects suffering from Prader-Willi Syndrome (PWS). The methods include administering compositions comprising probiotics, such as Lactobacillus reuteri (L. reuteri) and Bifidobacterium animalis subsp. lactis (B. Lactis) to subjects in need thereof.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/745 - Bifidobacteria
• A61K 36/064 - Saccharomycetales, e.g. baker's yeast
• A61K 38/27 - Growth hormone [GH], i.e. somatotropin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein are methods and systems utilizing CRISPR effector systems for assays and diagnostics. Embodiments herein provide tile probes in systems and methods for detection of multiple targets across a given genome or group of genomes, including in circulating nucleic acid samples.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• C12Q 1/682 - Signal amplification

Abstract

An oscillating scanning imaging system, including: a drive shaft including a proximal end and a distal end; an optical waveguide including a proximal end and a distal end, the proximal end of the optical waveguide being disposed within the proximal end of the drive shaft, and the distal end of the optical waveguide extending beyond the distal end of the drive shaft; an optical probe head coupled to the distal end of the optical waveguide; and an oscillating motor coupled to the drive shaft.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor

Abstract

Exemplary apparatus can be provided which can include a laser arrangement that is configured to provide a laser radiation, and including an optical cavity. The optical cavity can include a dispersive optical waveguide first arrangement having first and second sides, and which is configured to (i) receive at least one first electromagnetic radiation at the first side so as to provide at least one second electro-magnetic radiation, and (ii) to receive at least one third electro-magnetic radiation at the second side so as to provide at least one fourth electro-magnetic radiation. The first and second sides are different from one another, and the second and third radiations are related to one another. The optical cavity can also include an active optical modulator second arrangement which can be configured to receive and modulate the fourth radiation so as to provide the first electro-magnetic radiation to the first arrangement. The laser radiation can be associated with at least one of the first, second, third or fourth radiations.

IPC Classes  ?

• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01B 9/02091 - Tomographic interferometers, e.g. based on optical coherence
• G01K 11/32 - Measuring temperature based on physical or chemical changes not covered by group , , , or using changes in transmittance, scattering or luminescence in optical fibres
• H01S 3/067 - Fibre lasers
• H01S 3/08 - Construction or shape of optical resonators or components thereof
• H01S 3/106 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling devices placed within the cavity
• H03M 1/20 - Increasing resolution using an n bit system to obtain n + m bits, e.g. by dithering

Abstract

The present application provides compounds that are proteolysis targeting chimeras containing a celastrol-based ubiquitin ligase targeting moiety. Methods of using these compounds for treating various diseases, such as neurodegenerative diseases and cancer, are also provided.

IPC Classes  ?

• C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a monomeric immunogen comprising one receptor binding domain of a Coronavirus spike protein, wherein the receptor binding domain includes at least 4 non-native. N-linked, glycosylation sites.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present disclosure provides compounds having the formula F-L-N(R')H that are useful in imaging tissue remodeling and/or in diagnosing diseases such as myocardial infarction.

IPC Classes  ?

• C07D 311/82 - Xanthenes
• A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

Methods and constructs for RNA-guided targeting of heterologous functional domains such as transcriptional activators to specific genomic loci.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/10 - Transferases (2.)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 9/22 - Ribonucleases
• C12N 9/96 - Stabilising an enzyme by forming an adduct or a compositionForming enzyme conjugates
• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A modular analytic system includes a base, at least one fluid sample processing module configured to be removably attached to the base, at least one fluid sample analysis module configured to be removably attached to the base, a fluid actuation module positioned on the base, a fluidic network comprising multiple fluidic channels, in which the fluid actuation module is arranged to control transport of a fluid sample between the at least one sample processing module and the at least one sample analysis module through the fluidic network, and an electronic processor, in which the electronic processor is configured to control operation of the fluid actuation module and receive measurement data from the at least one fluid sample analysis module.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
• G01N 15/10 - Investigating individual particles
• G01N 15/12 - Investigating individual particles by measuring electrical or magnetic effects by observing changes in resistance or impedance across apertures when traversed by individual particles, e.g. by using the Coulter principle
• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 15/1434 - Optical arrangements
• G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation
• G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
• G01N 21/53 - Scattering, i.e. diffuse reflection within a body or fluid within a flowing fluid, e.g. smoke
• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor

Abstract

e.g.e.g.e.g., for treating neurodegenerative disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia. The present disclosure also provides piperidine-1-carboxylate compounds radiolabeled with a radioisotope, such as 11C, 18F, or 123/125I, and method of using the radiolabeled compounds for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) brain imaging agents for diagnosis and/or monitoring treatment of the neurodegenerative disorders.

IPC Classes  ?

• C07D 295/182 - Radicals derived from carboxylic acids
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

e.g.e.g.e.g., for treating neurodegenerative disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia.

IPC Classes  ?

• C08K 5/06 - EthersAcetalsKetalsOrtho-esters
• A61K 38/05 - Dipeptides

Abstract

e.g.e.g.e.g., for treating neurodegenerative disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia. The present disclosure also provides benzo[c][1,2,5]thiadiazolyl compounds radiolabeled with a radioisotope, such as 11C, 18F, or 123/125I, and method of using the radiolabeled compounds for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) brain imaging agents for diagnosis and/or monitoring treatment of the neurodegenerative disorders.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 471/04 - Ortho-condensed systems

Abstract

Described herein are fusion proteins comprising an extracellular domain of an immune checkpoint receptor and a cytoplasmic domain of an activating receptor. Also described herein are fusion proteins comprising a cytoplasmic domain of an immune checkpoint receptor and an extracellular domain of an activating receptor. The present disclosure further provides methods of use of such fusion proteins.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

e.g.e.g.e.g., for treating neurodegenerative disorders such as Parkinson's disease (PD), multiple system atrophy (MSA), and Lewy body dementia.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07K 5/06 - Dipeptides

Abstract

The invention features compositions and methods useful for targeting and activating translation, for example, non-canonical translation, in cancer cells.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A platform for creating engineered tissues includes a vascular tube that defines a vascular diameter and is configured to receive vascular system seed cells, a non-vascular tube that defines a non-vascular tube diameter and is configured to receive organ system seed cells, and a barrier formed between the vascular tube and the non-vascular tube.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61F 2/06 - Blood vessels
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/52 - Hydrogels or hydrocolloids
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A system for rigid motion correction for magnetic resonance imaging (MRI) of a subject includes an input for receiving motion corrupted k-space data for the subject acquired using an MRI system, a motion parameter estimation module coupled to the input and configured to estimate motion parameters based on the motion corrupted k-space data, a motion correction neural network coupled to the input and the motion parameter estimation module and configured to generate motion corrected k-space data based on the motion corrupted k-space data and the estimated motion parameters, and a reconstruction module coupled to the motion correction neural network and configured to generate a motion corrected image from the motion corrected k-space data.

IPC Classes  ?

• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G06T 11/00 - 2D [Two Dimensional] image generation

Abstract

One aspect of the invention provides a slurry comprising: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible surfactant. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; a biocompatible surfactant; and a foam comprising a plurality of gas bubbles. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible excipient. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a lipolytic agent.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 31/718 - Starch or degraded starch, e.g. amylose, amylopectin
• A61K 31/765 - Polymers containing oxygen
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Goods & Services

Providing courses of instruction in the fields of science, neuroscience, psychology, law, and legal systems; Providing online articles, amicus briefs, expert affidavits, and videos in the fields of science, neuroscience, law, and legal systems Providing information in the fields of scientific, medical, clinical, neuroscience, and legal research

Abstract

A systems and methods for monitoring cardiac function are provided. Electrocardiographic data is received and analyzed to identify an indication of prolongation of a depolarized phase or delay in repolarization. The electrocardiographic data is analyzed using the indication of prolongation to determine a probability of Torsades de Pointes (TdP). The probability of TdP is compared to a threshold. Upon determining a probability of TdP is above the threshold, an alarm is triggered to indicate the probability of TdP.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.

IPC Classes  ?

• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The invention features a method including characterizing a white blood cell sample from a patient using cytometry (e.g., CyTOF); wherein a deficiency in regulatory or suppressive immune cells and increased activated immune cells in the sample, relative to a healthy sample, indicates that the patient has amyotrophic lateral sclerosis (ALS).

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells

Abstract

The present invention discloses high-throughput methods for the creation of antibodies or antigen-binding fragments that can bind to single or multiple targets. Also disclosed are methods for using one or more antibodies or antigen-binding fragments to detect cognate binding partners in various types of samples.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Methods and compositions for a single- or multi-pot protocol for the efficient end to end capture of RNAs (inclusive of their poly-A tail or their 3′ end) is described. Capture oligonucleotides containing a 3′ non-extendable end and a selectively cleavable base upstream of an oligo-dT or oligo-dN and a 5′ sequence containing unique molecular identifiers, and 2) a deoxyuracil glycosylase that acts only on a deoxyuracil present in a DNA: DNA duplex or DNA/RNA heteroduplex are used. A dual template switching mechanism may be used.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing

Abstract

The present disclosure relates to compounds, e.g., compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof, and their use for modulating levels of progranulin.

IPC Classes  ?

• C07D 471/14 - Ortho-condensed systems
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines

Goods & Services

Downloadable software featuring information in the fields of healthcare, wellness, nutrition, and medicine; downloadable mobile application software for providing courses of instruction in the field of healthcare, wellness, nutrition, and medicine and distribution of course materials therewith; downloadable mobile application software for providing non-downloadable online videos featuring information on health care, wellness, nutrition, and medicine and distribution of materials therewith; downloadable videos featuring information in the fields of healthcare, wellness, nutrition, and medicine Providing courses of instruction in the field of health care, wellness, nutrition, and medicine and distribution of course materials therewith; providing continuing medical education courses and distribution of course materials therewith; medical training and teaching; Training services in the field of health care, wellness, nutrition, and medicine; educational services, namely, conducting programs in the field of health care, wellness, nutrition, and medicine and distribution of course materials therewith; providing non-downloadable online videos featuring information on health care, wellness, nutrition, and medicine and distribution of materials therewith; Production and distribution of videos in the field of health care, wellness, nutrition, and medicine education; providing an Internet website portal in the field of health care, wellness, nutrition, and medicine; providing an Internet website portal for supporting healthcare educators in the creation of videos featuring information on health care, wellness, nutrition, and medicine; providing an Internet website portal for supporting healthcare educators to be better educators Providing information in the field of health care, wellness, nutrition, and medicine; providing a web site featuring information in the field of health care, wellness, nutrition, and medicine

Abstract

A method and system for assessing tissue to determine a presence or absence of cancer cells. The method includes acquiring fluorescence lifetime (FLT) data from tissue and processing the FLT data to determine a FLT signal at each of a plurality of locations across the tissue. The method also includes determining FLT data at any of the plurality of locations above a threshold indicative a presence of cancer cells and generating a report indicating any of the plurality of locations above the threshold as indicative the presence of cancer cells.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present disclosure relates to chimeric proteins, or nucleic acid molecules, such as vectors, encoding chimeric proteins, capable of cleaving transfer RNA (tRNA molecules), thereby generating tRNA-derived small RNAs (tDRs). In particular, the chimeric proteins described herein contain a Cas domain and a ribonuclease domain and may be used to treat disease. The disclosure also features nucleic acid molecules that act as tDR mimics.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• A61K 38/46 - Hydrolases (3)

Abstract

Described herein are split and reduced size CRISPR Prime Editors, as well as variant reverse transcriptases, and methods of use thereof.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Devices and methods for improving the infection-healing behavior of a biological wound are disclosed. The device can comprise: a matrix; a light-emitting layer comprising a plurality of light sources; a controller in electrical communication with the light sources, the controller being configured to execute a program stored in the controller to activate the light sources to irradiate the wound or a region adjacent the wound with light for a period of time when the device is placed over the wound; and an antimicrobial adjuvant present as part of the device in an amount effective to synergistically potentiate antimicrobial activity of the light with respect to microbes on or adjacent the wound. The wound may include microbes in a biofilm. In one embodiment, the antimicrobial adjuvant comprises a substituted naphthalene, such as menadione. In one embodiment, the antimicrobial adjuvant comprises near infrared radiation.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61M 3/02 - EnemataIrrigators
• A61N 5/00 - Radiation therapy

Abstract

The present application relates to compounds of Formula (I') or Formula (II') and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating stathmin-2 (STMN2) activity and may be used in the treatment of disorders in which STMN2 activity is implicated, such as neurodegenerative diseases and disorders or axonopathy.

IPC Classes  ?

• C07D 213/44 - Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
• C07D 277/64 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• C07D 495/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Hand-held optical thromboelastographic sensor and method of using the same for simultaneous assessment of multiple parameters of blood coagulation at a point-of-care. The sensor includes an optical system registering laser speckle intensities associated with portions of a blood sample delivered through a fluid switch to analysis chambers of a cartridge of the sensor, and data-processing circuitry programmed to derive the multiple parameters from speckle intensity. The circuitry may be part of a mobile device configured to operate without communication with a central server and/or data storage.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 11/00 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• G01N 15/0205 - Investigating particle size or size distribution by optical means
• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/47 - Scattering, i.e. diffuse reflection
• G01N 21/51 - Scattering, i.e. diffuse reflection within a body or fluid inside a container, e.g. in an ampoule
• G01N 21/82 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

An apparatus for optical barcoding including: a microbead comprising one or more laser particles, the microbead being configured to generate one or more stimulated emission peaks hen energetically excited.

IPC Classes  ?

• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

Compositions and methods that are useful for identification of VHH antibodies that bind a target antigen.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
• C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof

Abstract

Single domain VHH polypeptides (antibodies) that bind mesothelin, VHH polypeptide products, methods, cells, pharmaceutical compositions, and kits. The VHH polypeptides may be recombinantly produced and expressed. Provided are also chimeric antigen receptor (CAR) polypeptides comprising the VHH polypeptides and CAR immune effector cells comprising the expressing the same.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 14/725 - T-cell receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are radiolabeled compounds useful for minimally invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for position emission tomography imaging of voltage gated sodium channels. Methods for prepared unlabeled and labeled compounds, and diagnostic methods using the compounds are also provided.

IPC Classes  ?

• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• A61K 51/04 - Organic compounds
• C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Abstract

An access device includes an access assembly for percutaneously accessing an anatomical space in a patient. An aspiration assembly is operable to generate negative pressure in a fluidic channel of the device. The fluidic channel places the access assembly in fluid connection with the aspiration assembly. A fluid tube has a first tube end connected to the access assembly, a second tube end connected to the aspiration assembly, and a tube body. The tube body defines a manometer tube portion spaced apart from both the first and second tube ends. The manometer tube portion acts as at least part of a manometer when the device is in a manometer mode. The manometer tube portion has adjacent first and second manometer tube ends and an inflection point substantially reversing the direction of the manometer tube portion at a location spaced apart from both the first and second manometer tube ends.

IPC Classes  ?

• A61M 39/02 - Access sites
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

The disclosure features compositions and methods that are useful for determining the fraction of tumor-derived DNA (tumor fraction; TF) in cell free DNA (cfDNA). The methods involve calculating the fraction of tumor-derived DNA in the cfDNA using a combination of copy number alteration data and fragment length distribution data.

IPC Classes  ?

• G16B 20/10 - Ploidy or copy number detection
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids

Abstract

The invention features a method for treating graft versus host disease in a human, including administering to said human a therapeutically effective amount of a cell including a chimeric antigen receptor (CAR) which is specifically directed against an immune checkpoint molecule.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors

Abstract

Immunogenic compositions comprising one or more peptides, wherein the one or more peptides: are capable of binding to Major Histocompatibility Complex (MHC) class II, and are derived from one or more translation products of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.

Abstract

Disclosed are zwitterion-containing copolymers and their use for creating functional surfaces on silicone-based materials. These copolymers are blended with silicone precursors at low concentrations before curing. The chemical structure of the copolymer additive leads it to segregate to the surface particularly upon contact with polar or aqueous media.

IPC Classes  ?

• C08L 83/04 - Polysiloxanes
• C08K 5/17 - AminesQuaternary ammonium compounds
• C08G 77/06 - Preparatory processes

Abstract

By example, a method for training a model to segment test images, wherein the test images comprise ultrasound image data, includes: receiving, at a self-supervised learning framework, a first plurality of training images, wherein the first plurality of training images include ultrasound data corresponding to patients' livers; processing the first plurality of plurality of training images with a learning algorithm of the self-supervised learning framework, and responsively adapting a trained model; and receiving, at a supervised learning framework, the trained model and a second plurality of training images, wherein the second plurality of training images include ultrasound data corresponding to patients' livers and annotations of the livers, and responsively adapting the trained model.

IPC Classes  ?

• G06V 10/778 - Active pattern-learning, e.g. online learning of image or video features
• A61B 8/08 - Clinical applications
• G06T 7/11 - Region-based segmentation

Abstract

Methods of treating and preventing fibrosis, and diseases/disorders characterised by fibrosis, through ADAMTS14 inhibition are disclosed, as well as agents for use in such methods.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

This disclosure is related to methods of preserving biological samples, organs. and organisms.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts

Abstract

Systems and methods are provided for digital witnessing of cellular structures. A system includes a processor and a non-transitory computer readable medium that stores instructions executable by the processor to provide an image interface configured to receive a first image and a similarity network. The similarity network compares the first image to a second image to determine a probability that the first and second images represent a same cellular structure or line of cellular structures. The similarity network is trained on a training set of samples, each including two images and a binary label. The training set includes positive examples, using two images of a same cellular structure or line of cellular structures, and negative examples, which use two images that are not of the same structure or line of cellular structures. An output device receives the probability or a categorical parameter representing the probability from the similarity network.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06N 3/045 - Combinations of networks
• G06N 3/0455 - Auto-encoder networksEncoder-decoder networks

Abstract

Disclosed herein are methods of eliciting an anti-cancer immune response by administering tumor-associated antigens, cells containing tumor-associated antigens, and/or nucleic acids encoding tumor-associated antigens. inducing immunogenic cell death in the cells expressing or containing the tumor-associated antigens. and optionally generating hyperactivated dendritic cells. Expression of tumor-associated antigens in a separate anatomical site generates a tumor avatar, which mimics the antigenic, but not immunosuppressive, environment of the tumor, with the generation of hyperactivated dendritic cells enhancing antigen presentation to elicit a robust anti-tumor T cell and antibody response. Also provided are compositions and kits containing nucleic acids and other components for use in the methods provided herein.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/125 - Picornaviridae, e.g. calicivirus
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 14/545 - IL-1
• C12N 5/0784 - Dendritic cellsProgenitors thereof

Abstract

Described herein are pancreatic ductal adenocarcinoma (PDAC) signatures and methods of detecting the same in a sample from a subject. Also described herein, are methods of methods of diagnosing, prognosing, and/or treating PDAC in a subject that can include detecting one or more of the PDAC signatures.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

By example, a method includes: receiving ultrasound image data of a patient, including a segmented region corresponding to a liver; automatically identifying an area for a region of interest within the segmented region, wherein the region of interest corresponds to a region in the liver for performing shear-wave elastography; and presenting, on a display, the ultrasound image data and the area for the region of interest.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation

Abstract

The present disclosure provides pharmaceutical compositions with improved mechanical strength and active pharmaceutical ingredients (API) elution properties useful for medical devices such as implants. Also provided are methods of making these compositions, which can include forming sub-micron particles of API and blending with a porous encapsulating material. In one embodiment, the methods can involve forming a solution of the API and precipitating particles thereof such as by adding a nonsolvent to the solution. The precipitated API can be mixing with the encapsulation media to form a blend, which can then be dried, dehydrated and molded to form a desired material, medical device, or implant.

IPC Classes  ?

• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

Systems and methods for a coupling a percutaneous device. The system can include a first coupling that can be configured to connect to a first catheter extending through a percutaneous opening in a patient, a second coupling that can be configured to connect to a second catheter to fluidly connect to the first catheter, and a failure-release that can be configured to automatically disconnect the fluid connection between the first catheter and the second catheter upon the system receiving a force at or above a predetermined threshold to protect the percutaneous opening in the patient from the force.

IPC Classes  ?

• A61M 39/10 - Tube connectors or tube couplings
• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61M 25/02 - Holding devices, e.g. on the body
• A61M 39/24 - Check- or non-return valves

Abstract

CXCL9SPP1SPP1 (CS) expression but not by conventional M1 and M2 markers, had a noticeably strong prognostic association. CS macrophage polarity also identified a highly coordinated network of either pro- or anti-tumor variables, which involved each tumor-associated cell type, and was spatially organized. The methods provided herein use tumor-associated macrophage (TAM) polarity as a variable for cancer prognosis.

Abstract

Systems and methods are provided for guiding a biopsy. The system includes an echograph system that provides an ultrasound image of a region of interest, a processor, an output device, and a non-transitory computer readable medium. Executable instructions on the medium provide a convolutional neural network that generates a predicted area for a biopsy needle from the ultrasound image. The convolutional neural network is trained on a plurality of ultrasound images with corresponding labelled images having an area representing the biopsy needle indicated by a human expert using a loss function that, for a given ultrasound training image and the corresponded labelled image, penalizes mismatches between the predicted area generated from the given ultrasound training image and the area indicated by the human expert on the corresponding labelled image. An output interface provides the ultrasound image to the output device with the predicted area for the biopsy needle indicated.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06N 20/20 - Ensemble learning
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 8/14 - Echo-tomography

Abstract

Provided herein are methods of producing plasmid libraries according to Current Good Manufacturing Practice (cGMP) guidelines.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
• C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
• C12N 15/65 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression using markers
• C12N 1/20 - BacteriaCulture media therefor

Abstract

Systems and methods are provided for performing a hair transplant using a hair transplant device. The hair transplant device includes a coring needle, a housing, and a user interface. The coring needle forms a coring lumen configured to extract a hair follicle from a donor site of a donor. The coring needle has a distal cutting end configured to move between an opened position and a closed position based on a heat memory of a material of the distal cutting end. The housing at least partially surrounds the coring needle, and the user interface extends from the housing and is movable relative to the coring needle to push the hair follicle from the coring lumen into a recipient site of a subject.

IPC Classes  ?

• A61B 17/3205 - Excision instruments
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/32 - Surgical cutting instruments
• A61B 17/34 - TrocarsPuncturing needles
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

A method of signal correction for dynamic confocal microscopy, including: directing a first portion of an output of a light source to a sample; collecting, using a first detector, first light returned from the sample to generate a sample image; directing a second portion of the output of the light source to a fiber Bragg grating; collecting, using a second detector, second light returned from the fiber Bragg grating to generate a reference image, the reference image including a plurality of rows; analyzing the reference image to identify an amount of delay in each row of the plurality of rows of the reference image; and producing a corrected sample image by adjusting each row of the plurality of rows of the sample image based on identifying the amount of delay in each row of the plurality of rows of the reference image.

Abstract

A method for acquiring a magnetic resonance image dataset of a subject is disclosed, wherein k-space is sampled during the acquisition in a plurality of k-space lines having different positions in the phase encoding direction. The method includes: sampling a first part of k-space by acquiring a number of k-space lines; determining a subject motion trajectory including motion data of the subject at one or several time points during the acquisition; associating the motion data with the positions along the phase encoding direction(s) of the k-space lines which were or will be acquired at the time points of the motion data; analyzing the distribution of the motion data in k-space and calculating a metric of variation of the motion data; and selecting the positions of the k-space lines of a next part of k-space to be acquired in the imaging protocol, depending on the metric of variation.

IPC Classes  ?

• G06T 7/20 - Analysis of motion
• G06T 5/20 - Image enhancement or restoration using local operators

Abstract

Provided herein are methods that use life or life-attenuated polyomavirus or an antigenic protein, protein fragment, or peptide thereof (e.g., HPyV6, MCPyV, and/or HPyV7) to block the type I interferon pathway and IL-33 induction, thereby protecting against autoimmune and inflammatory diseases, such as, but not limited to systemic lupus erythematosus.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/01 - DNA viruses

Abstract

Described herein is a 3D human neuroimmune axis model comprising human stem cell-derived neurons, astrocytes, microglia, and peripheral immune cells isolated from human blood. Also described herein are methods and compositions comprising CXCR3 inhibitors for treatment of Alzheimer's disease.

Abstract

New transgenic non-human animals comprising human Parathyroid Hormone 1 Receptor (hPTH1R), and methods of producing the same; new assays and screening techniques to evaluate the hPTH1R; and methods and transgenic animals to evaluate the response of hPTH1R to one or more candidate agents.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates

Abstract

Techniques are described for computer-implemented techniques for managing various aspects of the cardiac care pathway using machine learning. According to an embodiment, a method can include training an outcomes forecasting model to predict patient outcomes resulting from undergoing a cardiac valve procedure using multi-modal training data for a plurality of different patients, wherein the training comprising separately training different machine learning sub-models of the forecasting model to predict preliminary patient outcome data and mapping the preliminary patient outcome data to the patient outcomes, resulting in a trained version of the outcome forecasting model. The method further includes applying the trained version of the outcomes forecasting model to new multi-modal data for a new patient to predict the patient outcomes for the new patient resulting from undergoing the cardiac value procedure.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.

IPC Classes  ?

• C07K 14/55 - IL-2
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

An optical imaging system and method are provided for use with plasmon-enhanced optical imaging. The imaging system includes a multi-channel fluorescent microscope configured to image a sample on a plasmonic substrate; an image acquisition control unit configured to acquire multiple images at different times in a first channel; and an image processing unit configured to distinguish a signal within one or more of the multiple images as either (1) a signal from the sample or (2) a signal from a background hotspot.

IPC Classes  ?

• G01N 15/1433 - Signal processing using image recognition
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A soft robotic, 3D-printed simulator of heart function and disease has been designed to recreate the anatomy and function of specific people and patients with heart disease, for use personalized cardiovascular medicine. Using clinical imaging data, this system re-creates the anatomy of the left ventricle (the main pumping chamber of the heart) and of the aorta (the main blood vessel in the body). A soft robotic heart sleeve recapitulates the pumping action of the heart during normal physiology and disease. A soft robotic aortic sleeve can be added to the system to recapitulate disease of the aortic valve (separating the left ventricle and the aorta).

IPC Classes  ?

• G09B 23/32 - Anatomical models with moving parts

Abstract

Provided are compositions comprising inhibitory nucleic acids targeting SPP1, optionally linked to an antibody that targets macrophages such as TREM2, and methods of use thereof to treat atrial disease, e.g., AFib.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose

Abstract

Provided herein are methods for treating chronic kidney disease (CKD) in a subject in need thereof by administering to the subject a therapeutically effective amount of an inhibitor of one or more salt inducible kinases (SIKs). Also provided herein are inhibitors of one or more SIKs for use in treating, reducing the risk of occurrence, or delaying the occurrence of CKD in a subject. In some embodiments, the subject does not have acute kidney injury (AKI). In some embodiments, the subject does not have CKD Mineral and Bone Disorder (CKD-MBD). In some embodiments, the subject has early-stage CKD or intermediate-stage CKD.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

A method for magnetic resonance imaging includes performing a pre-scan using a spin-echo diffusion acquisition with a one-time MRI pulse sequence to measure phase differences between diffusion and non-diffusion acquisitions, which correspond to an estimation of eddy-current-induced phase in a diffusion-prepared sequence; and performing a scan using arbitrary waveform shim currents applied to a shim array during the acquisition, wherein the shim currents are determined from the measured phase differences from the pre-scan to create opposite phase maps to compensate eddy-current or system-imperfection-induced phase differences; wherein the scan and pre-scan are performed using an MRI apparatus with a channel integrated receiver and the shim array.

IPC Classes  ?

• G01R 33/3875 - Compensation of inhomogeneities using correction coil assemblies, e.g. active shimming

Abstract

Computer-implemented methods, computer program products, and systems determine an omics profiles of a cell using microscopy imaging data. In one aspect, a computer-implemented method determines an omics profiles of a cell using microscopy imaging data by a) receiving microscopy imaging data of a cell or a population of cells; b) determining a targeted expression profile of a set of target genes from the microscopy imaging data using a first machine learning model, the target genes identifying a cell type or cell state of interest; and c) determining a single-cell omics profile for the population of cells using a second machine learning algorithm model. The targeted expression profile and a reference single-cell RNA-seq data set are used as inputs for the second machine learning model. Computer-implemented methods, computer program products, and systems described herein also provide for determining single-cell omics profile from microscopy, such as Raman microscopy, or expression profiles, such as H&E stains.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 40/20 - Supervised data analysis

Abstract

Motion correction in spatiotemporal time-resolving magnetic resonance imaging (“MRI”) include a motion estimation component and a motion correction component. The motion estimation component can include a spatiotemporal time-resolved data acquisition that is configured to acquire navigator data in order to obtain motion parameters and estimate changed in B0 inhomogeneity caused by subject motion. Motion-corrected reconstruction can be used to recover accurate motion-corrected images by modeling the motion into the reconstruction. A subspace reconstruction framework can be used for both navigator reconstruction when estimating motion parameters, and for reconstructing the motion-corrected images.

IPC Classes  ?

• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G01R 33/24 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance for measuring direction or magnitude of magnetic fields or magnetic flux
• G01R 33/48 - NMR imaging systems
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences

Abstract

Laser particles and apparatus for generating plasmonic stimulated emission are provided, which particles include a semiconductor particle configured to provide a gain; and a metal layer disposed on at least one surface of the semiconductor particle, the metal layer configured to provide plasmons, wherein a size of the laser particle is less than 3 μm along its longest dimension.

IPC Classes  ?

• H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating

Abstract

A method for vascular regeneration comprises delivering endothelial cells to a lung scaffold, delivering perivascular cells to the lung scaffold, and providing a multiphase culture program to the scaffold. The multiphase culture program comprises a first phase including delivering an angiogenic medium, e.g., having 40-100 ng/ml of pro-angiogenic factors, and a second phase including delivering a stabilization medium, e.g., having 0.5-2% of serum and 1-20 ng/ml of angiogenic factors.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C07K 14/475 - Growth factorsGrowth regulators
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

Abstract

Described herein are compositions and methods that inhibit class I and IIb HIDACs for use in inhibiting NETosis and conditions associated with NETosis.

IPC Classes  ?

• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Methods for generating pre-epicardial cells (PECs) and/or cardiomyocytes (CMs) useful for cardiac tissue engineering, compositions comprising the cells, and methods of use thereof.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

Systems and methods of deep-learning diagnosis of plaque erosion using coronary computed tomography angiography (CTA). One system may include one or more electronic processors configured to receive a plurality of CTA images for a patient having acute coronary syndromes (ACS) and apply a machine learning model to the plurality of CTA images to determine a plaque erosion prediction.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06N 20/00 - Machine learning
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G06V 10/56 - Extraction of image or video features relating to colour
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment

Abstract

An apparatus for measuring a blood flow parameter in a blood vessel, including: an interferometric data collection apparatus including a light source and a sensor coupled to a controller, the controller being configured to: direct the light source toward a proximal side of a blood vessel; obtain interferometric data from a tissue adjacent to and outside of a distal side of the blood vessel opposite the proximal side; determine a signal modulation rate based on the interferometric data; and estimate a blood flow parameter in the blood vessel based on the signal modulation rate.

IPC Classes  ?

• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes

Abstract

Compounds, systems, and methods are provided for the design and assembly of a non-invasive, analyte sensing dressing. The dressing can be therapeutic. The dressing includes a sensor and a matrix. The sensor is capable of detecting analytes such as molecular oxygen, carbon dioxide, nitric oxides, dissolved analytes in plasma, and hydrogen ions. The matrix is at least partially permeable to the analyte. The device emits a detectable signal when the sensor is excited in the presence of the analyte. In one version of the dressing, the sensor includes a meso-unsubstituted metallated porphyrin that is sensitive towards oxygen. The metallated porphyrin can be excited when illuminated at a first wavelength, followed by emission of phosphorescence at a second wavelength whose intensity can be used as an indicator for oxygen concentration.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings

Abstract

Methods and compositions for contracting an expansion of CAG trinucleotide repeats in a huntingtin (HTT) gene in a cell, comprising Cas-based enzymes and a guide RNA (gRNA) that directs the Cas-based enzyme to the CAG nucleotide repeat.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

An implantable laminoplasty device is provided that can be used in minimally invasive surgery. The device includes a main housing with an inner housing slidably receivable by an outer housing. A gear is disposed in the main housing and engageable with a gear rack of the inner housing to adjust the length of the main housing. The gear defines an aperture configured to accept a tool to translate rotational movement into linear motion. A lock is slidably disposed in the main housing sized and configured to fix the length of the main housing when the desired length is achieved by slidable translation of the inner housing in the outer housing. The device also includes a laminar shelf portion and a lateral mass connection portion defining bone screws and both being hingedly connected to the main housing.

IPC Classes  ?

• A61F 2/44 - Joints for the spine, e.g. vertebrae, spinal discs
• A61F 2/30 - Joints

Abstract

In accordance with some configurations, systems and methods for guided removal from an in vivo subject are provided. In some configurations, a method for removing an object is provided. The method comprising, guiding a flexible tube through a passageway of an in vivo subject, wherein the flexible tube comprises at least a first passageway and a second passageway. Positioning a distal end of the first passageway in proximity to the object. Infusing liquid through the second passageway substantially continuously. Removing the object through the first passageway with at least a portion of the liquid while suction is not being provided.

IPC Classes  ?

• A61M 3/02 - EnemataIrrigators
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/307 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the urinary organs, e.g. urethroscopes, cystoscopes
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61B 17/34 - TrocarsPuncturing needles
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 18/26 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor for producing a shock wave, e.g. laser lithotripsy
• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61M 25/09 - Guide wires
• A61M 39/22 - Valves or arrangement of valves

Abstract

The disclosure provides compositions and methods for characterizing or treating a seizure disorder (e.g., focal epilepsy, temporal lobe epilepsy, mesial temporal lobe epilepsy, and related disorders).

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/282 - Platinum compounds

Abstract

The present disclosure features methods for modifying fertility. In some embodiments, the disclosure provides contraceptive compositions and methods of using the same.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 15/18 - Feminine contraceptives

Abstract

Provided herein are methods and compositions relating, in part, to the generation of human progenitor cells committed to the lung lineage and uses of such cells for treatment of lung diseases/disorders or injury to the lung. Whether an adult stem cell can be isolated from human adult lung remains controversial in the art and at present, methods for isolating and using adult lung stem cells from humans lack reproducibility. Thus, the methods and compositions described herein are advantageous over the present state of knowledge in the art and permit the generation of human lung progenitor cells for treatment, tissue engineering, and screening assays.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
• A61L 27/38 - Animal cells
• A61L 27/56 - Porous or cellular materials
• A61L 27/58 - Materials at least partially resorbable by the body
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G03B 21/28 - Reflectors in projection beam

Abstract

A method for detecting inflammatory activity, including: providing a catheter including a near-infrared fluorescence (NIRF) imaging system configured to perform NIRF imaging and an optical coherence tomography (OCT) imaging system configured to perform structural imaging; introducing a near-infrared fluorescent cathepsin-activatable imaging agent into a blood vessel; placing a distal end of the catheter within the blood vessel; obtaining, using the OCT imaging system, structural images of an atherosclerotic plaque within the blood vessel; obtaining, using the NIRF imaging system. NIRF images of the atherosclerotic plaque within the blood vessel; detecting the near-infrared fluorescent cathepsin-activatable imaging agent in the NIRF images; and identifying inflammation within the atherosclerotic plaque based on detecting the near-infrared fluorescent cathepsin-activatable imaging agent in the NIRF images.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The invention features methods and compositions for detection of an miRNA biomarker in an extracellular vesicle (e.g., a tumor-derived EV).

Abstract

The invention features compositions and methods for multiplexed, point-of-care compatible CRISPR assays for precise genotyping of human APOL1 variants.

IPC Classes  ?

• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases

Abstract

An active cannula robot system is provided. The system can include a housing with a proximal end and a distal end. The housing can surround a cannula unit, including two motors positioned proximally in the housing. The system can also include a carriage unit operably coupled and positioned distally to the two motors within the housing. The system can also include an active cannula tube extending longitudinally between and beyond the proximal end and distal end and configured to be actuated by the carriage unit. Also, the system can include a stationary cannula tube fixed to an outer surface of the distal end of the housing and extending distally and a processor configured to control the active cannula robot system.

IPC Classes  ?

• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 34/37 - Leader-follower robots
• A61B 17/34 - TrocarsPuncturing needles

Abstract

Methods and systems for (i) modulating, enhancing, or maintaining slow waves using phase-locked neurostimulation; (ii) modulating, enhancing, or maintaining unconsciousness using phase-locked neurostimulation; and (iii) reducing the amount of anesthesia required in a subject using phase-locked neurostimulation are provided. The present disclosure is directed to applying neurostimulation to the brain of a subject to enhance anesthesia, thereby decreasing drug requirements of anesthesia.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61N 1/04 - Electrodes

Abstract

Provided herein are engineered AAV capsids with improved biodistribution and transduction efficiency in the spinal cord and lowered biodistribution to liver, compositions comprising the capsids, and methods of using the same.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/86 - Viral vectors
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention features methods and compositions for concentrating target biomarkers by applying a combination of alternative current (AC) electroosmosis and dielectrophoresis (DEP), which bring target biomarkers toward the surface of a biosensor.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

Systems and methods are provided for monitoring nociception and/or pain in a patient. The system includes optodes configured be placed on the patient's scalp and forehead to acquire functional near-infrared spectroscopy (fNIRS) data from the medial frontopolar cortex (mFPC) region and the somatosensory (SI) regions of the patient. The system also includes a control unit coupled to the optodes. The control unit is to obtain the acquired fNIRS data from the optodes, process the acquired fNIRS data, and recognize signatures in the fNIRS data associated with a pain event in real time, where the signatures include measures of dissociation between the fNIRS data from the mFPC region and the fNIRS data from the SI region. The control unit is also configured to output a pain event classification to a user based on recognizing the signatures.

Abstract

Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 33/242 - GoldCompounds thereof
• A61K 33/243 - PlatinumCompounds thereof
• A61K 33/244 - LanthanidesCompounds thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention concerns compositions comprising an RNA molecule, wherein the RNA molecule comprises an expression cassette encoding an immunogenic peptide, which peptide comprises at least two fragments, wherein each fragment comprises at least one epitope, wherein the epitope is derived from an amino acid sequence encoded by the human immunodeficiency virus (HIV) and medical preparations comprising such compositions. Furthermore, the invention concerns methods for preventing or treating HIV.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/155 - Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus

Abstract

The invention provides compositions and methods for treating tuberous sclerosis complex (TSC). In particular, provided are condensed tuberins (cTuberins), cTuberin nucleic acids, and recombinant adeno-associated viruses (rAAVs) carrying a cTuberin nucleic acid for treating a patient with TSC.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors